The George Institute
Welcome,         Profile    Billing    Logout  
 23 Trials 
52 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Neal, Bruce C
START, NCT05345327: SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes

Recruiting
3
994
RoW
Dapagliflozin, Metformin
The George Institute, The University of New South Wales, Monash University, University of Sydney
Type 2 Diabetes
06/26
06/26
RAISED, NCT05912426: Preventing the Rise in Blood Pressure With Age Using Reduced-sodium Salt

Completed
N/A
148
RoW
Reduced-sodium potassium-enriched salt
The George Institute, University of Abuja Teaching Hospital
Blood Pressure
05/24
05/24
Litton, Edward
PREVENT-NEURO, NCT06819592: PRophylaxis Against Early VENTilator-associated Infections in Acute Brain Injury

Not yet recruiting
3
3100
RoW
Ceftriaxone 2g diluted in >200ml 0.9%sodium chloride, Placebo comparator - no ceftriaxone
The George Institute
All-cause Mortality, Quality of Life, Disability, Intellectual, Neurological Disorder, Acute Brain Injury, Ventilation, Mechanical, Intensive Care Medicine
03/28
01/29
Saxena, Manoj
REVISE, NCT03374800 / 2020-000483-27: Re-EValuating the Inhibition of Stress Erosions () Trial

Completed
3
4800
Europe, Canada, US, RoW
Placebo (0.9% saline), normal saline; NaCl 0.9%, Pantoprazole, Protonix
McMaster University, Canadian Institutes of Health Research (CIHR), Canadian Critical Care Trials Group, Australian and New Zealand Intensive Care Society Clinical Trials Group, National Health and Medical Research Council, Australia
Gastrointestinal Hemorrhage (Clinically Important, Upper)
10/23
01/24
ARISE FLUIDS, NCT04569942: Australasian Resuscitation In Sepsis Evaluation: FLUid or Vasopressors In Emergency Department Sepsis

Recruiting
3
1000
RoW
Vasopressor, Fluids
Australian and New Zealand Intensive Care Research Centre
Shock, Septic
10/25
12/26
PREVENT-NEURO, NCT06819592: PRophylaxis Against Early VENTilator-associated Infections in Acute Brain Injury

Not yet recruiting
3
3100
RoW
Ceftriaxone 2g diluted in >200ml 0.9%sodium chloride, Placebo comparator - no ceftriaxone
The George Institute
All-cause Mortality, Quality of Life, Disability, Intellectual, Neurological Disorder, Acute Brain Injury, Ventilation, Mechanical, Intensive Care Medicine
03/28
01/29
TTM-2, NCT02908308: Targeted Hypothermia Versus Targeted Normothermia After Out-of-hospital Cardiac Arrest

Completed
N/A
1900
Europe, US, RoW
Targeted temperature management to 33°C, Standard care with early treatment of fever
Helsingborgs Hospital, Lund University, Region Skåne - Skånevård SUND, Copenhagen Trial Unit, Center for Clinical Intervention Research, Clinical Trials Sweden, Forum South, Integrated Biobank of Luxembourg
Out-of-hospital Cardiac Arrest
06/22
12/22
STEPCARE, NCT05564754 / ACTRN12623001057673: Sedation, Temperature and Pressure After Cardiac Arrest and Resuscitation

Recruiting
N/A
3500
Europe, RoW
Feedback-controlled temperature device, High MAP, Deep sedation, Fever control without a device, Low MAP, Minimal sedation
Region Skane, Lund University, Lund, Sweden, Copenhagen Trial Unit, Center for Clinical Intervention Research, The George Institute for Global Health, Australia, HUS Helsinki University Hospitals, Helsinki, Finland, Medical Research Institute of New Zealand Rangahautia Te Ora, Wellington, New Zealand
Cardiac Arrest With Successful Resuscitation, Hypoxia, Brain
12/25
06/26
ACTRN12615001119583: Target Temperature Management for Traumatic Brain Injury: A Feasibility Study of Pyrexia Control

Not yet recruiting
N/A
50
 
The George Institute for Global Health, Intensive Care Foundation (Application in progress)
traumatic brain injury
 
 
ACTRN12615001119583p: Target Temperature Management for Traumatic Brain Injury: A Feasibility Study of Pyrexia Control

Not yet recruiting
N/A
50
 
The George Institute for Global Health, Intensive Care Foundation (Application in progress)
traumatic brain injury
 
 
ACTRN12611001218987: Early temperature and mortality in critically ill patients with neurological injury.

Not yet recruiting
N/A
20000
 
Australian and New Zealand Intensive Care Society Centre for Outcomes and Resource Evaluation, Australian and New Zealand Intensive Care Research Centre (ANZIC-RC) and the Intensive Care National Audit & Research Centre (ICNARC)
Ischamic and Haemorrhagic Stroke, including Subarachnoid Haemorrhage + Traumatic Brain Injury, Central Nervous System Infection
 
 
ACTRN12612000803897: Comparison of core and peripheral temperature measurement in adult critically ill patients with acute brain injury and sepsis

Recruiting
N/A
60
 
St George Hospital, Dr Manoj Saxena
Traumatic brain injury, Cardiac arrest, Stroke, Sepsis
 
 
Young, Paul
PREVENT-NEURO, NCT06819592: PRophylaxis Against Early VENTilator-associated Infections in Acute Brain Injury

Not yet recruiting
3
3100
RoW
Ceftriaxone 2g diluted in >200ml 0.9%sodium chloride, Placebo comparator - no ceftriaxone
The George Institute
All-cause Mortality, Quality of Life, Disability, Intellectual, Neurological Disorder, Acute Brain Injury, Ventilation, Mechanical, Intensive Care Medicine
03/28
01/29
REMAP-CAP, NCT02735707 / 2015-002340-14: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Recruiting
3
20000
Europe, Canada, Japan, US, RoW
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, IFN-β1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, acetylsalicylic acid, P2Y12 inhibitor, Clopidogrel, Prasugrel, Ticagrelor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Ramipril, Lisinopril, Perindopril, Enalapril, Trandolapril, Captopril, Angiotensin Receptor Blockers, Losartan, Valsartan, Candesartan, Irbesartan, Telmisartan, Olmesartan, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Paxlovid, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
UMC Utrecht, Australian and New Zealand Intensive Care Research Centre, Medical Research Institute of New Zealand, Unity Health, Berry Consultants, Global Coalition for Adaptive Research, University of Pittsburgh Medical Center, Intensive Care National Audit & Research Centre, St. Marianna University School of Medicine, Nat Intensive Care Surveillance - MORU, National University Hospital, Singapore
Community-acquired Pneumonia, Influenza, COVID-19
02/26
02/28
BoneZone, NCT04608630 / ACTRN12621000085875p: Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults

Recruiting
2
450
RoW
Denosumab 60 MG/ML, Prolia, Xgeva, Zoledronic Acid 5Mg/Bag 100Ml Inj, Zometa, Reclast, Aclasta, Sodium Chloride 0.9% or 5% Dextrose Intravenous, Saline, Placebo, Sodium Chloride 0.9% Injection
Australian and New Zealand Intensive Care Research Centre, Department of Health
Critical Illness, Osteoporosis
02/27
02/27
NCT06350734: Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study

Recruiting
N/A
704
US
Non-Interventional Study
Mayo Clinic
Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
01/29
01/29
TTM-2, NCT02908308: Targeted Hypothermia Versus Targeted Normothermia After Out-of-hospital Cardiac Arrest

Completed
N/A
1900
Europe, US, RoW
Targeted temperature management to 33°C, Standard care with early treatment of fever
Helsingborgs Hospital, Lund University, Region Skåne - Skånevård SUND, Copenhagen Trial Unit, Center for Clinical Intervention Research, Clinical Trials Sweden, Forum South, Integrated Biobank of Luxembourg
Out-of-hospital Cardiac Arrest
06/22
12/22
NCT06207942: Stepcare Extended Follow-up Substudy

Recruiting
N/A
600
Europe, RoW
Feed back controlled temperature device, High MAP, Deep sedation, Fever control without a device, Low MAP, Minimal sedation
Region Skane, Lund University, The George Institute for Global Health, Australia, Copenhagen Trial Unit, Center for Clinical Intervention Research, Helsinki University Central Hospital
Cardiac Arrest With Successful Resuscitation, Hypoxia, Brain, Cognitive Impairment, Caregiver Burden
06/26
12/26
BALANCE, NCT03005145: Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness

Completed
N/A
3622
Europe, Canada, US, RoW
7 days of adequate antibiotic treatment, 14 days of adequate antibiotic treatment.
Sunnybrook Health Sciences Centre
Bacteremia, Intensive Care, Critically Ill, Sepsis, Mortality, Antimicrobial
05/23
08/23
STEPCARE, NCT05564754 / ACTRN12623001057673: Sedation, Temperature and Pressure After Cardiac Arrest and Resuscitation

Recruiting
N/A
3500
Europe, RoW
Feedback-controlled temperature device, High MAP, Deep sedation, Fever control without a device, Low MAP, Minimal sedation
Region Skane, Lund University, Lund, Sweden, Copenhagen Trial Unit, Center for Clinical Intervention Research, The George Institute for Global Health, Australia, HUS Helsinki University Hospitals, Helsinki, Finland, Medical Research Institute of New Zealand Rangahautia Te Ora, Wellington, New Zealand
Cardiac Arrest With Successful Resuscitation, Hypoxia, Brain
12/25
06/26
Heerspink, Hiddo J Lambers
NCT04620590: An Open Label Phase IV Study to Evaluate Dapagliflozin Treatment in Type 2 Diabetes Mellitus Patients With Impaired Renal Function

Recruiting
4
17
Canada
Dapagliflozin 10 MG [Farxiga]
George Clinical Pty Ltd, University Medical Center Groningen, Ground Zero Pharmaceuticals
Diabetes Mellitus, Type 2, Impaired Renal Function
03/22
04/22
Optimize@Home, NCT06094920: Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial

Enrolling by invitation
4
10
Europe
Empagliflozin 10 MG, Jardiance, A10BK03, (2S,3R,4R,5S,6R)-2-[4-chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol, Finerenone, Kerendia, C03DA05, (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide, Withings BPM Connect, Withings Body, PeeSpot Urine Collection Device, Hem-Col Capillary Blood Collection Device, Questionnaire: participants' perspectives toward the feasibility of participation in a trial at home with digital technologies
University Medical Center Groningen, Boehringer Ingelheim
Diabetes Mellitus Type 2 With Proteinuria, Diabetes Mellitus, Type 2, Diabetes Mellitus, Diabetes, Diabetes Complications, Albuminuria, Chronic Kidney Diseases, Chronic Kidney Disease Due to Type 2 Diabetes Mellitus, Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, CKD, CKD Stage 3, CKD Stage 4
10/24
11/24
CAPTIVATE, NCT06058585: The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect

Recruiting
3
1000
RoW
Finerenone, BAY94-8862, Placebo Finerenone
The George Institute
Chronic Kidney Diseases
08/28
12/28
ZODIAC, NCT05570305 / 2021-001324-18: Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria

Enrolling by invitation
2
38
Europe, Canada, US
Zibotentan, Dapagliflozin, Placebo, Dapagliflozin and Zibotentan
University Medical Center Groningen, AstraZeneca
Chronic Kidney Diseases
04/24
09/24
ASPIRE, NCT06072326: Ambrisentan Sotagliflozin and Prevention of Renal Injury; a Randomized Evaluation

Not yet recruiting
2
36
Europe, Canada, US
Sotagliflozin, Ambrisentan, Ambrisentan and Sotagliflozin
University Medical Center Groningen, Juvenile Diabetes Research Foundation, Lexicon Pharmaceuticals
Type 1 Diabetes Mellitus With Diabetic Nephropathy
03/25
03/25
NCT04389827: Global Kidney Patient Trials Network

Recruiting
N/A
6000
RoW
The George Institute, George Clinical Pty Ltd
Kidney Diseases
04/25
04/30
Udy, Andrew
ACTRN12619001328167p: The BONANZA trial- a randomised controlled trial that is testing whether a management strategy guided by early brain tissue oxygen monitoring in patients in with severe traumatic brain injury improves long term neurological and functional outcomes.

Not yet recruiting
3
860
 
Australian and New Zealand Research Centre, School of Public Health and Preventive Medicine, Monash University, NHMRC
Severe traumatic brain injury
 
 
ACTRN12619001328167: The BONANZA trial- a randomised controlled trial that is testing whether a management strategy guided by early brain tissue oxygen monitoring in patients in with severe traumatic brain injury improves long term neurological and functional outcomes.

Recruiting
3
860
 
Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, NHMRC, Belgian Health Care Knowledge Centre (INV21-1323), Irish Health Research Board, Health Research Council of New Zealand (HRC Ref 21/937)
Severe traumatic brain injury
 
 
ARISE FLUIDS, NCT04569942: Australasian Resuscitation In Sepsis Evaluation: FLUid or Vasopressors In Emergency Department Sepsis

Recruiting
3
1000
RoW
Vasopressor, Fluids
Australian and New Zealand Intensive Care Research Centre
Shock, Septic
10/25
12/26
PREVENT-NEURO, NCT06819592: PRophylaxis Against Early VENTilator-associated Infections in Acute Brain Injury

Not yet recruiting
3
3100
RoW
Ceftriaxone 2g diluted in >200ml 0.9%sodium chloride, Placebo comparator - no ceftriaxone
The George Institute
All-cause Mortality, Quality of Life, Disability, Intellectual, Neurological Disorder, Acute Brain Injury, Ventilation, Mechanical, Intensive Care Medicine
03/28
01/29
ACTRN12620001361998p: SODium BICarbonate for metabolic acidosis in the Intensive Care Unit: A pilot, multicentre, double-blind, placebo controlled randomized clinical trial

Not yet recruiting
2
60
 
Australian and New Zealand Intensive Care Research Centre, Australian and New Zealand Intensive Care Research Centre
Metabolic acidosis
 
 
ACTRN12616000940471: A Phase II Feasibility study to determine the efficacy and dose-response of a single enteral dose of Ivabradine to reduce participant heart rate in patients admitted to the intensive care unit with sepsis and sinus tachycardia

Recruiting
2
20
 
A/Prof Andrew Udy,, The Alfred Research Trust: Alfred Small Projects Grants
Sepsis, tachycardia
 
 
ACTRN12620001361998: SODium BICarbonate for metabolic acidosis in the Intensive Care Unit: A pilot, multicentre, randomized, double-blind clinical trial

Terminated
2
60
 
Australian and New Zealand Intensive Care Research Centre, Australian and New Zealand Intensive Care Research Centre
Metabolic acidosis
 
 
ACTRN12618000199213: Paramedic administered antibiotics for patients with severe sepsis: Does this reduce the time to appropriate antibiotic therapy?

Terminated
2
110
 
Ambulance Victoria, Ambulance Victoria
Sepsis
 
 
FLASH, NCT06409364: FLudrocortisone Administration in Aneurysmal Subarachnoid Haemorrhage

Not yet recruiting
2
524
NA
Fludrocortisone, Flurinef, Placebo
The George Institute
Aneurysmal Subarachnoid Hemorrhage
07/29
07/30
NCT04896515: INTENT-Muscle (A Sub-study of INTENT)

Completed
N/A
21
RoW
Supplemental parenteral nutrition
Australian and New Zealand Intensive Care Research Centre
Critically Ill
02/23
02/23
NCT05542966: Blender Biomarkers: A BLENDER Sub-study to Evaluate the Effect of Oxygen Dose on Oxidative Stress and Organ Injury

Active, not recruiting
N/A
30
RoW
Australian and New Zealand Intensive Care Research Centre
Cardiac Failure, Critical Illness
08/23
12/23
NCT05855252: PRECISION-TBI - An Observational Study of Patients With Moderate to Severe Traumatic Brain Injury

Recruiting
N/A
300
RoW
No intervention
Australian and New Zealand Intensive Care Research Centre
Trauma, Brain
04/25
07/25
REDEEM, NCT05562505: Trial of Venovenous ECMO to De-Sedate, Extubate and Mobilise in Hypoxic Respiratory Failure

Recruiting
N/A
140
Europe, RoW
Venovenous ECMO
Australian and New Zealand Intensive Care Research Centre, The Alfred
Mechanical Ventilation Complication, Hypoxemia, Acute Respiratory Distress Syndrome Due to COVID-19, COVID-19 Respiratory Infection, Pneumonia, Extracorporeal Membrane Oxygenation
07/26
01/27
PNEUDOS, NCT04986254: PNEUmonia DOSing in Critically Ill Patients

Recruiting
N/A
80
Europe, RoW
Blood sampling, Epithelial lining fluid sampling, Urine sampling, Study antibiotics include benzylpenicillin, ceftriaxone, meropenem, and piperacillin/tazobactam
The University of Queensland, Royal Brisbane and Women's Hospital, The Alfred, University Hospital, Ghent, Centre Hospitalier Universitaire de Nīmes, Chinese University of Hong Kong, University of Malaya
Pneumonia
12/21
12/21
Jardine, Meg
RESOLVE, NCT02823821: Randomised Evaluation of Sodium Dialysate Levels on Vascular Events

Recruiting
4
50000
Europe, Canada, RoW
Default dialysate sodium concentration of 137mmol/l, Default dialysate sodium concentration of 140mmol/l
University of Sydney, Australasian Kidney Trials Network, Australia & New Zealand Dialysis & Transplant Registry, The George Institute for Global Health, India, The George Institute for Global Health, China, Peking University People's Hospital, Institute for Clinical Evaluative Sciences, St. Michaels Hospital, University Hospital Wuerzburg, Medizinische Klinik EINS, Malaysian Society of Nephrology, Malaysian Renal Registry, Comprehensive Clinical Trials Unit, University College London
End-Stage Kidney Disease
12/24
12/24
BEAT-Calci, NCT05018221: Better Evidence and Translation for Calciphylaxis

Recruiting
3
350
RoW
Vitamin K1, Phytonadione, Magnesium citrate, Sodium Thiosulfate, Intravenous Sodium Thiosulfate Injection, High Flux Dialyser, High Flux Hemodialysis, Medium Cut-off Dialyser, Medium Cut-off Hemodialysis, Placebo injection (normal saline), 0.9% sodium chloride solution, Placebo capsule (Vitamin K1), Matching placebo capsule, Placebo tablet (Magnesium citrate), Matching placebo tablet
University of Sydney, Australasian Kidney Trials Network, Northern Care Alliance NHS Foundation Trust, Waitemata District Health Board
Calciphylaxis
12/29
12/29
CLARITY 2, NCT05122182: Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19

Terminated
2
49
RoW
Candesartan Cilexetil, Repagermanium, DMX-200, Candesartan Placebo, Repagermanium Placebo
University of Sydney, The George Institute for Global Health, India
COVID-19, SARS-CoV2 Infection
08/22
01/23
Delaney, Anthony
REVISE, NCT03374800 / 2020-000483-27: Re-EValuating the Inhibition of Stress Erosions () Trial

Completed
3
4800
Europe, Canada, US, RoW
Placebo (0.9% saline), normal saline; NaCl 0.9%, Pantoprazole, Protonix
McMaster University, Canadian Institutes of Health Research (CIHR), Canadian Critical Care Trials Group, Australian and New Zealand Intensive Care Society Clinical Trials Group, National Health and Medical Research Council, Australia
Gastrointestinal Hemorrhage (Clinically Important, Upper)
10/23
01/24
ARISE FLUIDS, NCT04569942: Australasian Resuscitation In Sepsis Evaluation: FLUid or Vasopressors In Emergency Department Sepsis

Recruiting
3
1000
RoW
Vasopressor, Fluids
Australian and New Zealand Intensive Care Research Centre
Shock, Septic
10/25
12/26
PREVENT-NEURO, NCT06819592: PRophylaxis Against Early VENTilator-associated Infections in Acute Brain Injury

Not yet recruiting
3
3100
RoW
Ceftriaxone 2g diluted in >200ml 0.9%sodium chloride, Placebo comparator - no ceftriaxone
The George Institute
All-cause Mortality, Quality of Life, Disability, Intellectual, Neurological Disorder, Acute Brain Injury, Ventilation, Mechanical, Intensive Care Medicine
03/28
01/29
BEST-DKA, NCT05752279: Balanced Multi-Electrolyte Solution Versus Saline Trial for Diabetic KetoAcidosis

Not yet recruiting
3
680
RoW
Plasma-Lyte 148, Balanced multi-electrolyte solution, 0.9% sodium chloride, normal saline
The George Institute
Diabetic Ketoacidosis
04/26
06/26
FLASH, NCT06409364: FLudrocortisone Administration in Aneurysmal Subarachnoid Haemorrhage

Not yet recruiting
2
524
NA
Fludrocortisone, Flurinef, Placebo
The George Institute
Aneurysmal Subarachnoid Hemorrhage
07/29
07/30
NCT05855252: PRECISION-TBI - An Observational Study of Patients With Moderate to Severe Traumatic Brain Injury

Recruiting
N/A
300
RoW
No intervention
Australian and New Zealand Intensive Care Research Centre
Trauma, Brain
04/25
07/25
Kotwal, Sradha
CAPTIVATE, NCT06058585: The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect

Recruiting
3
1000
RoW
Finerenone, BAY94-8862, Placebo Finerenone
The George Institute
Chronic Kidney Diseases
08/28
12/28
NCT04389827: Global Kidney Patient Trials Network

Recruiting
N/A
6000
RoW
The George Institute, George Clinical Pty Ltd
Kidney Diseases
04/25
04/30
Lin, Enmoore
NCT04389827: Global Kidney Patient Trials Network

Recruiting
N/A
6000
RoW
The George Institute, George Clinical Pty Ltd
Kidney Diseases
04/25
04/30
Coggan, Sarah
No trials found

Download Options